Metastatic breast cancer: The role of pegylated liposomal doxorubicin after conventional anthracyclines

Cancer Treatment Reviews

Volumn 34, Issue 5, 2008, Pages 391-406

  Verma, Shailendra ^a   Dent, Susan ^a   Chow, Benjamin J W ^b   Rayson, Daniel ^c   Safra, Tamar ^d  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Anthracyclines; Breast neoplasms; Pegylated liposomal doxorubicin

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; IXABEPILONE; LAPATINIB; METHOTREXATE; MITOMYCIN C; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE;

ADJUVANT THERAPY; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RELAPSE; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFECTION; INJECTION SITE REACTION; JAUNDICE; LEUKOPENIA; LOADING DRUG DOSE; MAINTENANCE THERAPY; METASTASIS POTENTIAL; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; REVIEW; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; SYSTEMATIC REVIEW;

ANTHRACYCLINES; BREAST NEOPLASMS; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HUMANS; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 46749127029     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.01.008     Document Type: Review

References (55)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
2. Swain S.M., Whaley F.S., and Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97 (2003) 2869-2879
3. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20 (2002) 1215-1221
4. Bria E, Cuppone F, Fornier M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 2007. [published online 19.07.07].
5. O'Brien M.E.R., Wigler N., Inbar M., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCL (Caelyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15 (2004) 440-449
6. 2. Ann Oncol 11 (2000) 1029-1033
7. Batist G. Cardiac safety of liposomal anthracyclines. Cardiovasc Toxicol 7 2 (2007) 72-74
8. O'Shaughnessy J.A. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer 4 5 (2003) 318-328
9. Rivera E. Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist 8 Suppl. 2 (2003) 3-9
10. Lorusso V., Manzione L., and Silvestris N. Role of liposomal anthracyclines in breast cancer. Ann Oncol 18 Suppl. 6 (2007) vi70-vi73
11. Ranson M., Carmichael J., O'Byrne K., et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15 (1997) 3185-3191
12. Lyass O., Uziely B., Ben-Yosef R., et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89 5 (2000) 1037-1047
13. Schmid P., Schulz C.-O., Dieing A., et al. Biweekly pegylated liposomal doxorubicin (Caelyx/Doxil) in heavily pretreated patients with metastatic breast cancer. Breast Cancer Res Treat 81 (2004) 5059 [abstract]
14. Mlineritsch B., Mayer P., Rass C., et al. Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure. Onkologie 27 (2004) 441-446
15. Al-Batran S.-E., Bischoff J., von Minckwitz G., et al. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer 94 (2006) 1615-1620
16. 2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 70 (2006) 141-146
17. Coleman R.E., Biganzoli L., Canney P., et al. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer 42 (2006) 882-887
18. Yardley DA, Shipley DM, Greco FA, et al. Phase II randomized trial of pegylated liposomal doxorubicin vs. weekly docetaxel with subsequent crossover as first-line chemotherapy for metastatic breast cancer. In: Presented at the San Antonio breast cancer symposium; 2004 [Poster 5057].
19. Keller A.M., Mennel R.G., Georgoulias V.A., et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 22 (2004) 3893-3901
20. Alba E, Ruiz-Borrego M, Martin M, et al. Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001-01 study. J Clin Oncol 2007;25(18s):1007 [abstract updated from slides].
21. Overmoyer B., Silverman P., Holder L.W., Tripathy D., and Henderson I.C. Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin Cancer 6 (2005) 150-157
22. Vandenberg TA, Trudeau M, Provencher L, et al. Pegylated liposomal doxorubicin (PLD) with cyclophosphamide (C) as 1st-line chemotherapy for metastatic breast cancer (MBC) patients previously treated with adjuvant anthracyclines. J Clin Oncol 2006;24(18S):10627 [abstract].
23. Dufour PR, Rousseau F, Meyer N, et al. Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in elderly metastatic breast cancer patients. J Clin Oncol 2007;25(18S):19565 [abstract].
24. Rigatos S.K., Tsavdaridis D., Athananasiadis A., Stathopoulos J.G., and Stathopoulos G.P. Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a phase II study. Oncology Reports 10 (2003) 1817-1819
25. Siomoncini E, Ferrari VD, Amoroso V, et al. Bi-weekly administration of pegylated liposomal doxorubicin plus paclitaxel in metastatic breast cancer (MBC) patients: a phase II study. J Clin Oncol 2005;23(16S):844 (abstract).
26. Vorobiof D.A., Rapoport B.L., Chasen M.R., et al. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study. The Breast 13 (2004) 219-226
27. Alexopoulos A., Karamouzis M.V., Stavrinides H., et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol 15 (2004) 891-895
28. Guastalla JP, Largillier R, Geay JF, et al. Docetaxel (Do) and liposomal pegylated doxorubicin in metastatic breast cancer (MBC) patients (pts): The French GINECO group experience. J Clin Oncol 2006;24(18S):10589 [abstract].
29. Holmes F., Blum J.L., Kruger S., et al. Phase II study of weekly pegylated liposomal doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 82 Suppl. 1 (2003) 537 [abstract]
30. Morabito A., Gattuso D., Stani S.C., et al. Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer. Breast Cancer Res Treat 86 (2004) 249-257
31. Martin M., García-Donas J., Casado A., et al. Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure. Clin Breast Cancer 5 (2004) 353-357
32. Chow L.W.-C., Yun-San A., and Lang B.H.-H. A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer. Am J Clin Oncol 30 (2007) 133-138
33. Ardavanis A., Mavroudis D., Kalbakis K., et al. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study. Cancer Chemother Pharmacol 58 (2006) 742-748
34. Gebbia V., Mauceri G., Fallica G., et al. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. Oncology 63 (2002) 23-30
35. Rivera E., Valero V., Arun B., et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 21 (2003) 3249-3254
36. Fabi A., Ferretti G., Papaldo P., et al. Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naive and anthracycline pretreated metastatic breast cancer patients. Cancer Chemother Pharmacol 57 (2006) 615-623
37. Chia S., Clemons M., Martin L.-A., et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 24 (2006) 2773-2778
38. Wolff A.C., Wang M., Sparano J.A., Pins M.R., Thor A.D., and Davidson N.E. Cardiac safety and clinical activity of pegylated liposomal doxorubicin (D) and docetaxel (T) with and without trastuzumab (H) as 1st line chemotherapy in HER2-positive and HER2-negative metastatic breast cancer (MBC): Eastern Cooperative Oncology Group (ECOG) trial E3198. Breast Cancer Res Treat 88 Suppl. 1 (2004) S125 [abstract 3040]
39. Gennari A., Amadori D., De Lena M., et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24 (2006) 3912-3918
40. Cianfrocca ME, Rosen ST, von Roenn JH, et al. A phase I trial of pegylated liposomal anthracycline and lapatinib (L) combination in the treatment of metastatic breast cancer (MBC): first evaluation of an anthracycline and lapatinib combination in the treatment of MBC. J Clin Oncol 2007;25(18S):1079 [abstract].
41. Chuang E, Vahdat L, Caputo T, et al. Phase I clinical trial of ixabepilone and pegylated liposomal doxorubicin in patients with advanced breast or ovarian cancers: New York Cancer Consortium Trial P7729. J Clin Oncol 2007;25(18S):2570 [abstract].
42. Trudeau M, Madarnas Y, McCready D, Pritchard KI, Messersmith H, The Breast Cancer Disease Site Group. The role of trastuzumab in adjuvant and neoadjuvant therapy in women with HER2/neu-overexpressing breast cancer: a clinical practice guideline. Program in evidence-based care, a cancer Ontario program; 2006.
43. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: breast cancer - Version 2.2007. Available from: 2007.
44. Dahabreh I.J., Economopoulos K.P., and Murray S. Trastuzumab with adjuvant chemotherapy for resectable breast cancer: a meta-analysis. Ann Oncol 18 Suppl. 9 (2007) 29P [abstract]
45. Smith I., Procter M., Gelber R.D., et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy for HER2-positive breast cancer: a randomized controlled trial. Lancet 369 (2007) 29-36
46. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
47. Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23 (2005) 7811-7819
48. Slamon D., Eiermann W., Robert N., et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AT → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients. Br Cancer Treat Res (2006) [abstract 52]
49. Paik S., Bryant J., Park C., et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90 (1998) 1361-1370
50. Paik S., Bryant J., Tan-Chiu E., et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92 (2000) 1991-1998
51. Pritchard K.I., Shepherd L.E., O'Malley F.P., et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354 (2006) 2103-2111
52. Andreopoulou E., Gaiotti D., Kim E., et al. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 7 (2007) 690-696
53. Wilkes G.M., and Doyle D. Palmar-plantar erythrodysesthesia. Clin J Oncol Nurs 9 1 (2005) 103-106
54. Grenier N, Lebel V, Gill M, et al. Nursing support program to decrease or prevent side effects of pegylated liposomal doxorubicin (PLD) in patients with recurrent epithelial ovarian cancer (REOC). J Clin Oncol 2005;23(16S):8198 [Part I of II (June 1 Suppl.), abstract].
55. Coates A.S., Stockler M., and Wilcken N. Controversies in metastatic breast cancer: optimal duration of chemotherapy. Am Soc Clin Oncol Ed Book (2003) 119-121